-
71.发明授权公开(公告)号：US11832842B2
公开(公告)日：2023-12-05
申请号：US16614970
申请日：2018-05-16
申请人： SUMITOMO BAKELITE CO., LTD. , NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
CPC分类号： A61B17/30 , A61M39/10 , A61B2017/00477 , A61B2017/308 , A61B2217/005 , A61M2039/1038 , A61M2210/125
摘要： The present invention provides a coronary artery bypass surgery treatment tool or the like including a flexible tube, a suction cup in which an opening portion is formed to communicate with the flexible tube and which is provided at a distal end of the flexible tube, a joint portion which has a suction path, a male connector which is provided in one of a proximal end of the flexible tube and a distal end of the suction path of the joint portion, and a female connector which is provided in the other thereof and is detachably connected to the male connector.
-
72.发明公开公开(公告)号：US20230346318A1
公开(公告)日：2023-11-02
申请号：US18128561
申请日：2023-03-30
发明人： Makoto YASUKAWA , Shuhei NOYORI , Kosuke Nishihara , Yuki Kosaka , Akimoto Nimura , Koji Fujita , Takuya Ibara
CPC分类号： A61B5/7235 , A61B5/0803 , A61B5/7275
摘要： An information processing apparatus inputs expiratory phase data being data of expiratory phase and inspiratory phase data being data of inspiratory phase, for each of abdominal waveform data indicating a breathing waveform of an abdomen of a subject performing breathing training and chest waveform data indicating a breathing waveform of a chest of the subject. The information processing apparatus calculates a phase difference between the abdominal waveform data and the chest waveform data in each of the expiratory phase and the inspiratory phase.
-
73.发明授权公开(公告)号：US11773376B2
公开(公告)日：2023-10-03
申请号：US16630188
申请日：2018-07-12
发明人： Hiroshi Asahara , Kensuke Kataoka , Tomoki Chiba
CPC分类号： C12N5/066 , A61L27/225 , A61L27/3683 , A61L27/386 , A61L27/3834 , A61L2430/10 , C12N2506/45 , C12N2527/00 , C12N2533/54 , C12N2533/56
摘要： The present invention relates to providing artificial tendon or ligament tissue having sufficient strength. More specifically, artificial tendon or ligament tissue having sufficient strength is provided by embedding collagen-secreting cells in a gel having strength capable of resisting a tensile load and by culturing the cells while applying a tensile load to the gel to produce artificial tendon or ligament tissue. Cells that steadily express the Mkx gene can be used as the collagen-secreting cells. A fibrin gel containing aprotinin can be used as the gel.
-
公开(公告)号：US20230212492A1
公开(公告)日：2023-07-06
申请号：US18008915
申请日：2021-06-07
申请人： National University Corporation Tokyo Medical and Dental University , Takeda Pharmaceutical Company Limited
发明人： Takanori TAKEBE , Norikazu SAIKI
CPC分类号： C12M21/08 , C12M23/02 , C12N5/0062 , C12N5/0068 , A61P9/10 , C12M29/10 , C12M25/02 , C12N2533/90 , C12N2513/00
摘要： The present invention provides a culture method capable of maturing an organoid through long-term culture, and suitable for producing a conformational organ. The culture method of the present invention is a method for culturing an organoid and/or cells constituting an organ immobilized in a chamber with a culture fluid perfused, and the culture fluid is perfused in such a manner as to generate a turbulent flow in the chamber.
-
公开(公告)号：US11692244B2
公开(公告)日：2023-07-04
申请号：US16634921
申请日：2018-07-24
摘要： An alloy for biomedical use includes Zr as a main component, Nb the content of which is not less than 0.1% by weight and not greater than 25% by weight, Mo the content of which is not less than 0.1% by weight and not greater than 25% by weight, and Ta the content of which is not less than 0.1% by weight and not greater than 25% by weight. A tensile strength of the alloy is not less than 1000 MPa. A total content of Nb, Mo, and Ta in the alloy is not less than 2% by weight and not greater than 50% by weight. Mass susceptibility of the alloy is not greater than 1.50×10−6 cm3/g. A Young's modulus of the alloy is not greater than 100 GPa. Also disclosed is a medical product including the alloy and a method for producing the alloy.
-
76.发明公开公开(公告)号：US20230191096A1
公开(公告)日：2023-06-22
申请号：US17998609
申请日：2021-05-13
CPC分类号： A61M31/002 , A61K9/0053 , A61K33/00 , A61K31/02 , A61P7/00 , A61M2230/20 , A61M2205/3344 , A61M2210/1064
摘要： A pharmaceutical composition may be used in administering oxygen to a subject. The pharmaceutical composition may contain a perfluorocarbon dissolving oxygen therein. Further, a pharmaceutical composition may be used in decreasing the blood carbon dioxide partial pressure of a subject, and the pharmaceutical composition may contain a perfluorocarbon. Such a composition may be suitable for administered oral administration, nasogastric administration, trans-fistula gastric administration, or administration into a large intestine.
-
公开(公告)号：US11674141B2
公开(公告)日：2023-06-13
申请号：US16975441
申请日：2019-02-27
发明人： Takanori Yokota , Satoru Ishibashi
IPC分类号： A61K48/00 , C12N15/113 , A61K47/54 , A61P9/10 , A61K9/00
CPC分类号： C12N15/113 , A61K9/0019 , A61K47/543 , A61K47/549 , A61P9/10 , C12N2310/11 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12N2310/3519 , C12N2320/32
摘要： The present invention provides an antisense nucleic acid medicine that can modulate expression of a target transcriptional product in an ischemic site of a subject. The present invention also provides a composition for modulating expression of a target transcriptional product in an ischemic site of a subject, having a nucleic acid complex formed by annealing together a first nucleic acid strand having an antisense oligonucleotide region with respect to the target transcriptional product, and a lipid-conjugated second nucleic acid strand having a complementary region that is complementary to at least part of the first nucleic acid strand.
-
公开(公告)号：US20230174981A1
公开(公告)日：2023-06-08
申请号：US17906444
申请日：2021-03-12
发明人： Takanori YOKOTA , Tetsuya NAGATA
IPC分类号： C12N15/113 , A61K31/713
CPC分类号： C12N15/113 , A61K31/713 , C12N2310/11 , C12N2310/3233 , C12N2310/3515 , C12N2320/32 , C12N2310/314
摘要： A double-stranded nucleic acid complex that can have an excellent activity is provided. In one embodiment, the present invention relates to a double-stranded nucleic acid complex having a first nucleic acid strand and a second nucleic acid strand. The first nucleic acid strand is capable of hybridizing to at least part of a target gene or a transcription thereof, has an antisense effect on the target gene or transcription product thereof, and has at least two morpholino nucleic acids The second nucleic acid strand has a base sequence complementary to the first nucleic acid strand. The first nucleic acid strand is annealed to the second nucleic acid strand.
-
公开(公告)号：US11666759B2
公开(公告)日：2023-06-06
申请号：US17069193
申请日：2020-10-13
申请人： Shinji Sato , Sukchan Kim , Taishi Watanabe , Yuki Mitani , Yuki Miyano , Shigenori Kawabata , Toru Sasaki
发明人： Shinji Sato , Sukchan Kim , Taishi Watanabe , Yuki Mitani , Yuki Miyano , Shigenori Kawabata , Toru Sasaki
IPC分类号： A61N1/36
CPC分类号： A61N1/36031 , A61N1/36034
摘要： A nerve stimulating apparatus includes a plurality of stimulating units configured to respectively apply stimuli to a plurality of nerve regions branching from a particular nerve region of a living body, and a stimulation timing controller configured to set generating timings of respectively generating the stimuli at the plurality of stimulating units. The stimulation timing controller sets the generating timings of generating the stimuli at the plurality of stimulating units based on response results of the particular nerve region, the response results being obtained in response to the stimuli that are respectively generated at the plurality of stimulating units and that are respectively applied to the plurality of nerve regions, and the response results being measured by a biometric information measuring apparatus that measures biometric information.
-
公开(公告)号：US20230132346A1
公开(公告)日：2023-04-27
申请号：US18146109
申请日：2022-12-23
发明人： Ichiro SEKIYA , Mitsuru MIZUNO , Hisako KATANO , Nobutake OZEKI , Kentaro NAKAMURA , Tomomi YOSHIDA
IPC分类号： C12N5/0775 , C12N9/64 , A61P19/00
摘要： An object of the present invention is to provide a production method for a synovium-derived mesenchymal stem cell, which makes it possible to obtain a sufficient amount of synovium-derived mesenchymal stem cells from the synovial tissue, a production method for a cell preparation for joint medical treatment using the production method for a synovium-derived mesenchymal stem cell, synovium-derived mesenchymal stem cell, and a cell preparation for a joint medical treatment. According to the present invention, there is provided a production method for a synovium-derived mesenchymal stem cell, which includes treating a synovial tissue with an enzyme for 2 hours or more; and washing a mixture after the enzyme treatment until a residual enzyme concentration in a supernatant is 0.5 ng/mL or less, to obtain a synovium-derived mesenchymal stem cell.
-
-
-
-
-
-
-
-
-
搜索结果
303 条记录 (耗时 0.032 秒)
